#USA #California #Class Action #Securities Fraud #Hims & Hers

Attention Hims & Hers Health, Inc. Investors

Investors who purchased Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025, and July 29, 2026, may be entitled to participate in a class action lawsuit. This significant legal development comes in response to allegations of securities fraud leveled against the company, leading to potential recovery options for affected investors.

Overview of the Lawsuit

The class action lawsuit, filed in the United States District Court for the Northern District of California, has been organized by Kessler Topaz Meltzer Check, LLP, a respected law firm known for its expertise in securities litigation. The complaint highlights key allegations related to material misstatements and omissions regarding Hims & Hers' privacy practices, which have raised serious concerns among investors.

According to the lawsuit, the company failed to disclose critical information about how it handled consumer health data. Specifically, the allegations state that Hims shared sensitive health information with third-party advertising platforms, creating a breach of trust with its customers. Furthermore, it was claimed that Hims charged consumers for prescriptions almost immediately after they filled out intake forms, contrary to assurances that they could consult a medical provider about treatment options.

The Impact of Regulatory Action

The legal troubles escalated when the Federal Trade Commission (FTC) brought a lawsuit against Hims on July 29, 2026, accusing the firm of deceptive privacy practices. The fallout from this lawsuit saw Hims' stock price plummet by 14.73%, closing at $25.00 per share on the same day. Such a drastic decline underscores the gravity of the situation and the potential losses faced by investors.

Investor Action Required

For those who have suffered financial losses due to this situation, time is of the essence. Investors have until November 2, 2026, to file for lead plaintiff status in this case. Lead plaintiffs play a pivotal role in guiding the lawsuit and representing the interests of other affected individuals. If you are interested in pursuing this option or seeking further information, Kessler Topaz Meltzer Check, LLP is encouraging affected investors to reach out for a free case evaluation.

How to Get Involved

Investors can take several actions at this juncture:

• - File to be the lead plaintiff before the deadline of November 2, 2026.
• - Contact Kessler Topaz Meltzer Check, LLP for a free evaluation of your case. Importantly, all legal representation offered by KTMC is done on a contingency fee basis, meaning there are no upfront costs to those seeking legal recourse.
• - Choose to retain your own counsel or to remain an absent class member without action.

About Kessler Topaz Meltzer Check, LLP

The law firm involved in this case, Kessler Topaz Meltzer Check, LLP, has a strong reputation for advocating on behalf of investors and securing substantial recoveries for their clients in securities litigation. Their expertise includes representing individual fund holders as well as major institutional investors. The firm has been recognized numerous times, including accolades for their accomplishments in class action lawsuits representative of shareholder interests.

If you purchased Hims & Hers Health securities during the outlined period and are interested in discussing your legal rights, the firm extends an invitation to contact attorney Jonathan Naji for further information. Given the case's complexity and potential implications for investors, seeking professional legal guidance is highly advisable.

In conclusion, the unfolding situation at Hims & Hers Health, Inc. presents an avenue for affected investors to reclaim their losses through legal action. With a firm filing a class action lawsuit on their behalf, it is crucial for investors to act promptly to ensure they protect their rights.